With an FDA approval for its pricey CAR-T therapy Yescarta under its belt and more treatments in the pipeline, Gilead’s Kite Pharma was on the hunt for a new manufacturing site to fuel those hopes. The company found it in Maryland.
{iframe}https://www.fiercepharma.com/pharma/new-maryland-facility-to-boost-kite-s-car-t-manufacturing-ability{/iframe}